This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Clarke, P. Articles by Holman, R. Search for Related Content PubMed PubMed Citation Articles by Clarke, P. Articles by Holman, R. Social Bookmarking                         What's this?

Estimating Utility Values for Health States of Type 2 Diabetic Patients Using the EQ-5D (UKPDS 62)

Health Economic Research Centre, Department of Public Health, University of Oxford, Institute of Health Sciences, Oxford, United Kingdom

Alastair Gray, PhD

Health Economic Research Centre, Department of Public Health, University of Oxford, Institute of Health Sciences, Oxford, United Kingdom

Rury Holman, FRCP

Diabetes Trials Unit, Radcliffe Infirmary, Oxford, United Kingdom

Purpose. The aim of this study was to analyze quality-of-life data from the United Kingdom Prospective Diabetes Study (UKPDS) to estimate the impact of diabetes-related complications on utility-based measures of quality of life. Methods. The EuroQol EQ-5D instrument was administered in 1996 to 3667 UKPDS patients with type 2 diabetes. Tobit and censored least absolute deviations (CLAD) regression analysis based on data from the 3192 respondents was used to estimate the impact of major complications on (1) the visual analog scale (VAS) and (2) the EQ-5D utilities derived from population-based time trade-off values. Results. Using the tobit model, the effect on tariff values was as follows: myocardial infarction = -0.055 (95% confidence interval [CI] = -0.067, -0.042), blindness in 1 eye = -0.074 (95% CI = -0.124, -0.052), ischemic heart disease = -0.090 (95% CI = -0.126, -0.054), heart failure = -0.108 (95% CI = -0.169, -0.048), stroke = -0.164 (95% CI = -0.222, -0.105), and amputation = -0.280 (95% CI = -0.389, -0.170). The impact on the VAS scores was smaller, but the ranking was identical. Estimates of these effects, based on the nonparametric CLAD estimator, are also reported and compared. Conclusion. These results demonstrate the magnitude of the impact of 6 complications on utility-based measures of quality of life, which can be used to estimate the outcome of interventions that reduce these diabetes-related complications.

Key Words: diabetes • utility • EQ-5D • quality of life • visual analog scale • diabetes-related complications

Medical Decision Making, Vol. 22, No. 4, 340-349 (2002)
DOI: 10.1177/0272989X0202200412


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				B. T. Denton, M. Kurt, N. D. Shah, S. C. Bryant, and S. A. Smith Optimizing the Start Time of Statin Therapy for Patients with Diabetes Med Decis Making, May 1, 2009; 29(3): 351 - 367. [Abstract] [PDF]

				P. Gaede, W. J. Valentine, A. J. Palmer, D. M.D. Tucker, M. Lammert, H.-H. Parving, and O. Pedersen Cost-Effectiveness of Intensified Versus Conventional Multifactorial Intervention in Type 2 Diabetes: Results and projections from the Steno-2 study Diabetes Care, August 1, 2008; 31(8): 1510 - 1515. [Abstract] [Full Text] [PDF]

				J. Bottomley Economic costs of diabetes in the US in 2007 -- Implications for Europe The British Journal of Diabetes & Vascular Disease, March 1, 2008; 8(2): 96 - 100. [Abstract] [PDF]

				E. S. Huang, S. E.S. Brown, B. G. Ewigman, E. C. Foley, and D. O. Meltzer Patient Perceptions of Quality of Life With Diabetes-Related Complications and Treatments Diabetes Care, October 1, 2007; 30(10): 2478 - 2483. [Abstract] [Full Text] [PDF]

				P. W. Sullivan and V. Ghushchyan Mapping the EQ-5D Index from the SF-12: US General Population Preferences in a Nationally Representative Sample Med Decis Making, July 1, 2006; 26(4): 401 - 409. [Abstract] [PDF]

				P. M. Clarke, J. Simon, C. A. Cull, and R. R. Holman Assessing the Impact of Visual Acuity on Quality of Life in Individuals With Type 2 Diabetes Using the Short Form-36 Diabetes Care, July 1, 2006; 29(7): 1506 - 1511. [Abstract] [Full Text] [PDF]

				J. Bottomley, A. J Palmer, R. Williams, J. Dormandy, and M. Massi-Benedetti Review: PROactive 03: Pioglitazone, type 2 diabetes and reducing macrovascular events -- economic implications? The British Journal of Diabetes & Vascular Disease, March 1, 2006; 6(2): 63 - 70. [Abstract] [PDF]

				D. G. Manuel and S. E. Schultz Health-Related Quality of Life and Health-Adjusted Life Expectancy of People With Diabetes in Ontario, Canada, 1996-1997 Diabetes Care, February 1, 2004; 27(2): 407 - 414. [Abstract] [Full Text] [PDF]

				K. M. V. Narayan, J. P. Boyle, T. J. Thompson, S. W. Sorensen, and D. F. Williamson Lifetime Risk for Diabetes Mellitus in the United States JAMA, October 8, 2003; 290(14): 1884 - 1890. [Abstract] [Full Text] [PDF]